DOD Pharmacy & Therapeutics Committee

On March 10, 2025, the Secretary of Defense directed a pause of all DOD Advisory Committees, including the Uniform Formulary Beneficiary Advisory Panel meeting.  As a result, the upcoming UF BAP meeting is delayed, and posting of the February 2025, May 2025, and August 2025 P&T Committee meeting minutes will be delayed. Congressional mandate requires that the UF BAP comment publicly on the DD P&T Committee recommendations, prior to signing by the Director, DHA. Until the UF BAP is re-established, the DOD P&T Committee meeting minutes are not available. Please check the UF BAP website for any updates on upcoming UF BAP meeting dates.

The Department of Defense Pharmacy & Therapeutics Committee's mission is to uniformly, consistently, and equitably provide appropriate drug therapy to meet the clinical needs of DOD beneficiaries in an effective, efficient, and fiscally responsible manner.

DOD P&T Committee Meeting Schedule

View DOD P&T Meeting Minutesopens to DOD P&T Meeting Minutes See Archived Meeting Pagesopens to Archived Meeting Pages

November 5-6, 2025

Uniform Formulary Request for Quote Information

  • UF BPA and UF ADP Class Quotes Due: September 22, 2025 at 12 p.m. CT

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Utilization Management
  • INSULINS – RAPID-ACTING AGENTS U-100
    • Admelog
    • Apidra
    • Fiasp
    • Humalog
    • Insulin Aspart
    • Insulin Lispro
    • Lyumjev
    • Merilog
    • Novolog
  • INSULINS – RAPID-ACTING AGENTS U-200
    • Humalog
    • Lyumjev
  • METABOLIC DYSFUNCTION AGENTS - INJECTABLE DIABETIC AGENTS
    • Bydureon Bcise
    • Byetta
    • Exenatide
    • Mounjaro
    • Ozempic
    • Semaglutide
    • Tirzepatide
    • Trulicity
  • METABOLIC DYSFUNCTION AGENTS – INJECTABLE WEIGHT LOSS AGENTS
    • Saxenda
    • Wegovy
    • Zepbound

 

  • Anzupgo
  • Brinsupri
  • Brynovin
  • Ekterly
  • Harliku
  • Hernexeos
  • Kirsty
  • Lopressor
  • Modeyso
  • Orlynvah
  • Sephience

 

 

August 6-7, 2025

Uniform Formulary Request for Quote Information

  • UF BPA and UF ADP Class Quotes Due: June 26 at 12 p.m. CT

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Utilization Management
  • ATOPY -  ATOPY: IL-13, IL-31
    • Adbry
    • Dupixent
    • Ebglyss
    • Nemluvio
  • DIURETICS – MINERALOCORTICOID RECEPTOR ANTAGONISTS
    • Kerendia
  • Andembry
  • Arbli
  • Avmapki Fakzynja Co-pack
  • Combogesic
  • Ensacove
  • Hemiclor
  • Ibtrozi
  • Imuldosa
  • Khindivi
  • Merilog
  • nilotinib tartrate
  • Qfitlia
  • Symbravo
  • Tezruly
  • Tryptyr
  • ustekinumab
  • ustekinumab-aekn
  • Vanrafia
  • Vyvgart Hytrulo
  • Yutrepia
  • Zelsuvmi

 
  • Admelog
  • Anoro Ellipta
  • Apidra
  • Benlysta
  • Bisoprolol
  • buspirone
  • clemastine
  • Corlanor
  • diflunisal
  • Doptelet
  • Eohilia
  • escitalopram
  • Fabhalta
  • flurbiprofen
  • Gemtesa
  • GLP1s
  • Isturisa
  • Lutrate Depot
  • metformin
  • Myrbetriq
  • Nucala
  • Rinvoq
  • Welireg
  • Yonsa
  • Zarxio
  • Zoryve
  • Zytiga

 

May 7-8, 2025

Uniform Formulary Request for Quote Information

  • UF BPA and UF ADP Class Quotes Due: March 20 at 12 p.m. CT

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs  Utilization Management
  • BREAST CANCER AGENTS; CYCLIN DEPENDENT KINASE INHIBITOR
    • Ibrance
    • Kisqali
    • Verzenio
  • TARGETED IMMUNODULATORY BIOLOGICS: INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4)
    • Actemra
    • Arcalyst 
    • Enspryng
    • Kevzara
    • Kineret
    • Orencia
    • Tyenne
  • Alhemo
  • Gomekli
  • Inzirqo
  • Journavx
  • Otulfi
  • Prevymis
  • Pyzchiva
  • Raldesy
  • Romvimza
  • Selarsdi
  • Steqeyma
  • ustekinumab-ttwe
  • Vykat XR
  • Xromi
  • Yesintek
  • Zunveyl
  
  • Bylvay
  • Calquence
  • Contrave
  • Emverm
  • Entresto
  • Eucrisa
  • Imcivree
  • Inrebic
  • Korlym
  • Koselugo
  • Livmarli
  • Lumakras
  • Metformin
  • Mounjaro
  • Namenda XR
  • Nuplazid
  • Odactra
  • Ozempic
  • Pomalyst
  • Qinlock
  • Rydapt
  • Saxenda
  • Tabrecta
  • Tecfidera
  • Tepmetko
  • Tramado
  • Tremfya
  • Turalio
  • Uloric
  • Urea
  • Vanflyta
  • Vitrakvi
  • Vizimpro
  • Wegovy
  • Xenical
  • Xospata
  • Zepbound
  • Zileuton

February 5-6, 2025

Uniform Formulary Request for Quote Informationopens to Uniform Formulary Request for Quote Information

  • UF BPA and UF ADP Class Quotes Due: December 30, 2024 at 12 p.m. CT

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs  Utilization Management
  • NARCOTIC ANALGESICS AND COMBINATION – BUPRENORPHINE & COMBINATIONS
    • Belbuca
    • Zubsolv
  • SLEEP DISORDERS - WAKEFULNESS PROMOTING AGENTS
    • Lumryz
    • sodium oxybate
    • Sunosi
    • Wakix
    • Xyrem
    • Xywav
  • Alyftrek
  • Attruby
  • Crenessity
  • Danziten
  • Emrosi
  • Hympavzi
  • Itovebi
  • Imkeldi
  • Miplyffa
  • Nypozi
  • Omnipod 5 Libre 2Plus G6
  • Opipza
  • Revuforj
  • Tryngolza
  • Wezlana
  
  • Amitiza
  • Bimzelx
  • Braftovi
  • Cibinqo
  • Dupixent
  • Enbrel
  • Entyvio
  • Frova
  • Linzess
  • Naratriptan
  • Nemluvio
  • Olumiant
  • Omvoh
  • Restasis
  • Rinvoq
  • Scemblix
  • Skyrizi OBI
  • Sotyktu
  • Stelara
  • tramadol 75 mg
  • Tremfya
  • Tridacaine XL
  • Trintellix
  • Vtama
  • Vyvanse
  • Xeljanz
  • Zepbound
  • Zymfentra

Nov. 6-7, 2024

Uniform Formulary Request for Quote Informationopens to Uniform Formulary Request for Quote Information

Uniform Formulary Request for Quote Informationopens to Uniform Formulary Request for Quote Information

  • UF BPA and UF ADP RFQ Documents Posted: July 18, 2024
  • Pre-Proposal Teleconference: July 24, 2024 at 1 p.m. CT
  • UF BPA and UF ADP Class Quotes Due: Sept. 19, 2024 at 12 p.m. CT

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Utilization Management
  • MIGRAINE AGENTS - ORAL CGRP:

    • Nurtec ODT

    • Qulipta

    • Ubrelvy

  • TARGETED IMMUNOMODULATORY BIOLOGICS - INTERLEUKIN 17 (IL-17):

    • Bimzelx 

    • Cosentyx

    • Siliq 

    • Taltz 

  • TARGETED IMMUNOMODULATORY BIOLOGICS - INTERLEUKIN 23 (IL-23):

    • Ilumya

    • Omvoh

    • Skyrizi

    • Stelara

    • Tremfya

  • Aqneursa

  • Clobetasol propionate ophthalmic suspension

  • Cobenfy

  • Crexont

  • Ebglyss

  • Femlyv

  • Lazcluze

  • Livdelzi

  • Neffy

  • Nemluvio

  • Ohtuvayre

  • Onyda XR

  • Sofdra

  • Tryvio

  • Vafseo

  • Vigafyde

  • Voranigo

  • Yorvipath

  • Zepbound

 

 

 

Aug. 7-8, 2024

Uniform Formulary Request for Quote Informationopens to Uniform Formulary Request for Quote Information

Uniform Formulary Request for Quote Information opens Uniform Formulary Request for Quote Information

  • UF BPA and UF ADP RFQ Documents Posted: April 22, 2024
  • Pre-Proposal Teleconference: April 24, 2024 at 1 p.m. CT
  • UF BPA and UF ADP Class Quotes Due: June 13, 2024 at 12 p.m. CT

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Utilization Management
  • ANTILIPIDEMICS-1 AGENTS - NON-STATIN and COMBOS:

    • Nexletol

    • Nexlizet

  • ANTILIPIDEMICS-1 AGENTS - STATINS:

    • Altoprev

    • Atorvaliq 

    • Ezallor Sprinkle

    • Flolipid

    • Zypitamag

  • LEUKEMIA and LYMPHOMA  AGENTS - BRUTON TYROSINE KINASE INHIBITORS:

    • Brukinsa

    • Calquence

    • Imbruvica

    • Jaypirca

  • Duvyzat

  • Humira (Cordavis)

  • Iqirvo

  • Libervant TM

  • Myhibbin

  • Ojemda

  • Opsynvi

  • Rextovy

  • Rezdiffra

  • Simlandi

  • Sitagliptin/metformin 

  • Spevigo

  • Tyenne

  • Voydeya

  • Winrevair

  • Xolremdi

 

 

 

May 1-2, 2024

Uniform Formulary Request for Quote Informationopens to Uniform Formulary Request for Quote Information

Uniform Formulary Request for Quote InformationUniform Formulary Request for Quote Information (New Drug Class) (New Drug Class)opens to Uniform Formulary Request for Quote Information (New Drug Class)

  • UF BPA and UF ADP RFQ Documents Posted: Jan. 31, 2024
  • Pre-Proposal Teleconference: Jan. 31, 2024 at 1 p.m. CT
  • UF BPA and UF ADP Class Quotes Due: Mar. 21, 2024 at 12 p.m. CT

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Utilization Management
  • INSULINS - BASAL:

    • Basaglar Kwikpen U-100

    • Basaglar Tempo Pen U-100

    • Insulin Degludec

    • Insulin Degludec Pen U-100

    • Insulin Degludec Pen U-200

    • Insulin Glargine

    • Insulin Glargine Solostar

    • Insulin Glargine-YFGN

    • Lantus

    • Lantus Solostar

    • Levemir

    • Levemir Flexpen

    • Levemir Flextouch

    • Rezvoglar Kwikpen

    • Semglee

    • Semglee-YFGN

    • Semglee-YFGN Pen

    • Semglee Pen

    • Toujeo Max Solostar

    • Toujeo Solostar

    • Tresiba

    • Tresiba Flextouch U-100

    • Tresiba Flextouch U-200

  • WEIGHT LOSS AGENTS - NA:

    • Apidex-P

    • Contrave

    • Lomaira

    • Orlistat

    • Qsymia

    • Saxenda

    • Wegovy

    • Xenical

    • Zepbound

  • PULMONARY II AGENTS - INHALED CORTICOSTERIODS:

    • Alvesco

    • Armonair Digihaler

    • Arnuity Ellipta

    • Asmanex

    • Asmanex HFA

    • Flovent Diskus

    • Flovent HFA

    • Fluticasone Propionate HFA

    • Pulmicort Flexhaler

    • Qvar Redihaler

  • Agamree

  • Alvaiz

  • Bosulif

  • Eohilia

  • Fabhalta

  • Filsuvez

  • Iwilfin

  • Rivfloza

  • Vevye

  • Wainua

  • Xolair Auto-injector

  • Zilbrysq

  • Zituvio

  • Zoryve

  • Zymfentra

 

 

 

Feb. 7-8, 2024

Uniform Formulary Request for Quote Informationopens to Uniform Formulary Request for Quote Information

  • UF BPA and UF ADP RFQ Documents Posted: Oct. 26, 2023
  • Pre-Proposal Teleconference: Nov. 8, 2023 at 1 p.m. CT
  • UF BPA and UF ADP Class Quotes Due: Dec. 21, 2023 at 12 p.m. CT

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Utilization Management
  • GROWTH STIMULATING AGENTS - NA:

    • Genotropin

    • Humatrope

    • Ngenla

    • Norditropin Flexpro

    • Nutropin AQ Nuspin

    • Omnitrope

    • Saizen

    • Saizen-Saizenprep

    • Serostim

    • Skytrofa

    • Sogroya

    • Zomacton

  • Abrilada

  • Augtyro

  • Bimzelx

  • Cabtreo

  • Coxanto

  • Entyvio

  • Fruzaqla

  • Jesduvroq

  • Jylamvo

  • Likmez

  • Motpoly XR

  • Ogsiveo

  • Ojjaara

  • Omvoh

  • Truqap

  • Velsipity

  • Voquezna

  • Xalkori

  • Xphozah

  • Zepbound

  • Zurzuvae
  • PRIOR AUTHORIZATION UPDATES:

    • Adbry

    • Besremi

    • Cosentyx

    • Enbrel

    • Forteo

    • Jaypirca

    • Lidocan

    • Lynparza

    • Mektovi

    • Nubeqa

    • Orencia

    • Pokonza

    • Rozlytrek

    • Tibsovo

    • Venclexta

    • Voxzogo

    • Welireg

    • Xtandi

    • Yonsa

    • Zoryve

    • Zytiga

If the DOD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.

Subject to Change Disclaimer

The Defense Health Agency reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.